Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs

Fineline Cube Feb 12, 2026
Company Deals

Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Fineline Cube Feb 12, 2026
Company Drug

Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...

Company Drug

Sisram Medical’s Profhilo Accepted for Review by China’s NMPA

Fineline Cube Dec 12, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196),...

Company Drug

Staidson Pharmaceutical Initiates Clinical Study for ARDS Treatment STSA-1002

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing...

Company Medical Device

Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System

Fineline Cube Dec 12, 2023

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Drug

Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...

Company Medical Device

Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval

Fineline Cube Dec 12, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...

Company Drug

Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA

Fineline Cube Dec 12, 2023

Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...

Company Deals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

Fineline Cube Dec 12, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...

Company Deals

Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine

Fineline Cube Dec 12, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...

Company Deals

Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China

Fineline Cube Dec 12, 2023

Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...

Policy / Regulatory

CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20

Fineline Cube Dec 11, 2023

The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...

Company Drug

Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC

Fineline Cube Dec 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...

Company Deals

Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform

Fineline Cube Dec 11, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies

Fineline Cube Dec 11, 2023

Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...

Company Deals

Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging

Fineline Cube Dec 11, 2023

Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...

Company Drug

MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints

Fineline Cube Dec 11, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...

Company Drug

Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer

Fineline Cube Dec 11, 2023

Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...

Company

Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District

Fineline Cube Dec 11, 2023

Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...

Company Drug

Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis

Fineline Cube Dec 8, 2023

Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a...

Company Deals

Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin

Fineline Cube Dec 8, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement...

Posts pagination

1 … 389 390 391 … 624

Recent updates

  • Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
  • Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
  • Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
  • MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
  • Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.